Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Co-founder and Chief Scientific Officer, Christopher Kirk, will participate in the “Novel Targets for Autoimmune Diseases” panel discussion at William Blair's Biotech Focus Conference on Thursday, July 15, 2021, at 11:00 a.m. ET.

A live webcast of the panel may be accessed at the “Events & Presentations” section of Kezar’s website at http://investors.kezarlifesciences.com/events. Kezar Life Sciences will maintain an archived replay of the webcast on its website for 90 days after the conference.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company bringing novel treatments to patients with rare autoimmune diseases and cancer. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. KZR-616, its lead development candidate, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis and polymyositis. Additionally, KZR-261, the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway, is undergoing IND-enabling activities. For more information, visit www.kezarlifesciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005060/en/